BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA
China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...
BeOne Medicines
Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...
CDE Indicates Priority Review for Overland ADCT’s Zynlonta and BeiGene’s Brukinsa
The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)...
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...
BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...
Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...
BeiGene’s Tislelizumab Approved in China for First-Line Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has been approved...
BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients
China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...
BeiGene’s Tislelizumab Secures First Approvals Outside China Mainland in Macau
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...
BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval...
BeiGene Reports Q1 2023 Financial Growth, Advances Pipeline with Global Expansion Plans
China-based BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has reported financial results for the...
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...
BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...
BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...